Transdermal Scopolamine Market Is Progressing at a Healthy CAGR of 6.70% Between 2016 and 2024
The opportunity in the global transdermal scopolamine market was pegged at US$330.0 mn in 2015 and is poised to reach a valuation of US$585.3 mn by the end of 2024, progressing at a healthy CAGR of 6.70% between 2016 and 2024.
View full press release